Clinical trials
Withdrawn Liver Cirrhosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2023 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 26 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Montefiore Medical Center | 2 |
| A2 Healthcare Taiwan Corporation | 1 |
| Air Force Military Medical University, China | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| British Columbia Cancer Agency | 1 |
| Chinese University of Hong Kong | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Galecto Biotech AB | 1 |
| Institute of Liver and Biliary Sciences, India | 1 |
| Jae Ho Byun | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Cirrhosis | 26 |
| Carcinoma, Hepatocellular | 3 |
| Fibrosis | 3 |
| Hepatic Encephalopathy | 3 |
| Liver Diseases | 3 |
| Ascites | 2 |
| Hepatitis C | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Brain Damage, Chronic | 1 |
| Brain Diseases | 1 |
Trials
Showing 76 to 26 of 26. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.